Corvus Pharmaceuticals announces initiation of Phase 2 trial of soquelitinib
Corvus Pharmaceuticals (CRVS) announced that the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes ...
The Manila Times49m
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
This is the third indication under clinical development for soquelitinib, which is also in a registrational Phase 3 trial for peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic ...